Journal of Medicinal Chemistry · 2004 · 161 citations · 27 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyAntineoplastic Drug ClassesCyclin-dependent KinasesHit-to-lead OptimizationLead Compound DesignLead DiscoveryBioactivity In Vitro TestingCancer-associated Cyclin-dependent KinasesCdk InhibitorsCyclin E FamilyCyclin-dependent Kinase InhibitorsHit-to-lead Library ExpansionIn Vivo Efficacy TestingKinase Inhibitor Library Design
Abnormal proliferation mediated by disruption of the normal cell cycle mechanisms is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDK) and cyclins, such as CDK2/cyclin A and CDK2/cyclin E, and inhibiting their kinase activity are regarded as promising antitumor agents to complement the existing therapies. From a high-throughput screening effort, we identified a new class of CDK2/cyclin A/E inhibitors. The hit-to-lead expansion of this class is described. X-ray crystallographic data of early compounds in this series, as well as in vitro testing funneled for rapidly achieving in vivo efficacy, led to a nanomolar inhibitor of CDK2/cyclin A (N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthyl)acetamide (41), PNU-292137, IC50 = 37 nM) with in vivo antitumor activity (TGI > 50%) in a mouse xenograft model at a dose devoid of toxic effects.
27
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
Philip D. Jeffrey, Alicia A. Russo, Kornélia Polyák et al. · Nature · 1995 · 1.4K citations
Cyclin A is required at two points in the human cell cycle.
Michele Pagano, Rainer Pepperkok, Fulvia Verde et al. · The EMBO Journal · 1992 · 1.4K citations · Full text